| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, Fmoc-HoCys(ACM)-OH has no specific biological target. Its role is to provide homocysteine residues in peptide chains with the thiol group protected. The Fmoc protecting group enables standard Fmoc solid-phase peptide synthesis (SPPS) workflows. The Acm group provides protection for the thiol during peptide synthesis, preventing unwanted oxidation or side reactions. The compound does not interact with enzymes or receptors in pharmacological assays. Its "target" is the peptide coupling reaction, where it acts as a protected amino acid donor.
|
|---|---|
| ln Vitro |
Compound 1 (Fmoc-HoCys(ACM)-OH) can be employed in solid phase peptide synthesis by the application of a Fmoc-based approach[1].
The in vitro activity of Fmoc-HoCys(ACM)-OH is measured by coupling efficiency in solid-phase peptide synthesis (SPPS). Typically, it is coupled to resin-bound amine using standard Fmoc-SPPS conditions: deprotection of the resin-bound Fmoc group with 20% piperidine in DMF, followed by coupling with Fmoc-HoCys(ACM)-OH (typically 3-5 equivalents) using coupling reagents such as HATU, HBTU, or DIC with HOBt, and DIEA as base. Coupling efficiency is monitored by the Kaiser test or by quantitative HPLC. Purity is typically ≥98%. No inherent biological activity is observed as the compound is a protected amino acid derivative. |
| ln Vivo |
In vivo activity is not applicable for Fmoc-HoCys(ACM)-OH. The compound is not used in animals and is a research chemical for laboratory synthesis only.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for Fmoc-HoCys(ACM)-OH involves standard Fmoc solid-phase peptide synthesis procedures. Standard SPPS cycle: deprotect Fmoc with 20% piperidine in DMF (typically 2 × 5-10 minutes), wash with DMF, couple Fmoc-HoCys(ACM)-OH (3 equiv.) with HATU (2.9 equiv.) and DIEA (6 equiv.) for 1-2 hours, wash, repeat. After complete assembly of the peptide sequence, the peptide is cleaved from the resin and deprotected using a cleavage cocktail containing TFA, TIS, and water (typically 95:2.5:2.5) for 2-4 hours. The compound's SMILES is O=C(O)[C@@H](NC(OCC1C2=C(C3=C1C=CC=C3)C=CC=C2)=O)CCSCNC(C)=O.
|
| Cell Assay |
In vitro cell-based experimental workflows are not performed on this intermediate. The final deprotected peptides may be tested in cell-based assays, but the protected compound itself is not used.
|
| Animal Protocol |
In vivo animal experiments are not applicable for Fmoc-HoCys(ACM)-OH.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties have not been characterized. The compound is not a drug. The compound is stable under recommended storage conditions: powder at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
The toxicological data are limited. Standard laboratory safety practices should be followed. The compound is intended for research use only.
|
| References |
[1]. Lutgring R, et, al. Synthesis of homologs of cysteine suitable for peptide and protein crosslinking. Bioorganic & Medicinal Chemistry Letters. 1993 Apr; 3(4): 739-742.
|
| Additional Infomation |
Fmoc-HoCys(ACM)-OH is an Fmoc-protected homocysteine derivative featuring an Acm protecting group on the thiol. The compound is a homologue of cysteine and can be synthesized from L-methionine. It is used in solid-phase peptide synthesis using an Fmoc-based strategy. It is not a drug and has no clinical trials or approvals. The compound is for research use only.
|
| Molecular Formula |
C22H24N2O5S
|
|---|---|
| Molecular Weight |
428.50
|
| Exact Mass |
428.14
|
| CAS # |
150281-21-3
|
| PubChem CID |
56777174
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
731.2±60.0 °C at 760 mmHg
|
| Flash Point |
396.0±32.9 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.611
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
30
|
| Complexity |
594
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)NCSCC[C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
|
| InChi Key |
LKXJXPIRDOELQS-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C22H24N2O5S/c1-14(25)23-13-30-11-10-20(21(26)27)24-22(28)29-12-19-17-8-4-2-6-15(17)16-7-3-5-9-18(16)19/h2-9,19-20H,10-13H2,1H3,(H,23,25)(H,24,28)(H,26,27)/t20-/m0/s1
|
| Chemical Name |
(2S)-4-(acetamidomethylsulfanyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (233.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3337 mL | 11.6686 mL | 23.3372 mL | |
| 5 mM | 0.4667 mL | 2.3337 mL | 4.6674 mL | |
| 10 mM | 0.2334 mL | 1.1669 mL | 2.3337 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
